$AVTX
Avalo Therapeutics, Inc. Stock $avtx

$avtx Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000162828022004671 Filed on March 02, 2022

Income Statement

Concept	2022 Q1	2021	2020 Q4
Revenue	$1.173M	$5.398M	$1.496M
YoY Change	147.99%	-19.42%	157.96%
Cost Of Revenue	$720.0K	$1.491M	$79.42K
YoY Change	835.06%	397.0%	58.84%
Gross Profit	$453.0K	$3.907M	$1.417M
YoY Change	14.39%	-38.94%	162.36%
Gross Profit Margin	38.62%	72.38%	94.69%
Selling, General & Admin	$11.68M	$24.66M	$4.618M
YoY Change	118.56%	24.79%	52.92%
% of Gross Profit	2579.25%	631.12%	325.96%
Research & Development	$9.584M	$59.84M	$12.64M
YoY Change	283.36%	85.86%	334.36%
% of Gross Profit	2115.67%	1531.48%	892.17%
Depreciation & Amortization	$67.00K	$1.657M	$538.3K
YoY Change	-85.14%	-10.09%	-11.75%
% of Gross Profit	14.79%	42.41%	37.99%
Operating Expenses	$21.27M	$84.49M	$17.76M
YoY Change	171.07%	62.64%	184.09%
Operating Profit	-$20.85M	-$82.13M	-$16.34M
YoY Change	-31.81%	12.75%	186.15%
Interest Expense	-$1.169M	-$2.391M	$48.87K
YoY Change	-6976.47%	-4979.59%	-62.41%
% of Operating Profit
Other Income/Expense, Net	-$1.189M	-$2.411M	-$37.04K
YoY Change	-7094.12%	-142.55%	-47.09%
Pretax Income	-$22.04M	-$84.55M	-$16.33M
YoY Change	-27.88%	25.86%	188.47%
Income Tax	$9.000K	-$196.0K	-$185.4K
% Of Pretax Income
Net Earnings	-$22.10M	-$84.40M	-$15.64M
YoY Change	-27.97%	32.91%	-1065.6%
Net Earnings / Revenue	-1884.06%	-1563.54%	-1045.5%
Basic Earnings Per Share	-$2.35
Diluted Earnings Per Share	-$2.346M	-$10.14M	-$208.6K
COMMON SHARES
Basic Shares Outstanding	112.8M shares		74.91M shares
Diluted Shares Outstanding	9.400M shares

Balance Sheet

Concept	2022 Q1	2021	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$38.47M	$54.59M	$18.92M
YoY Change	0.46%	188.51%	68.32%
Cash & Equivalents	$38.50M	$54.59M	$18.92M
Short-Term Investments			$0.00
Other Short-Term Assets	$2.782M	$2.423M	$2.697M
YoY Change	6.26%	-10.17%	119.3%
Inventory	$25.00K	$38.00K	$3.000K
Prepaid Expenses
Receivables	$938.0K	$1.060M	$2.177M
Other Receivables	$1.445M	$3.739M	$2.208M
Total Short-Term Assets	$43.66M	$61.85M	$26.01M
YoY Change	-5.29%	137.82%	46.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.604M	$2.695M	$1.607M
YoY Change	70.2%	67.7%	11.01%
Goodwill	$14.41M		$14.41M
YoY Change	0.0%		0.0%
Intangibles	$0.00		$1.585M
YoY Change	-100.0%		-34.67%
Long-Term Investments
YoY Change
Other Assets	$1.227M	$1.227M	$148.6K
YoY Change	723.49%	725.48%	48.64%
Total Long-Term Assets	$18.24M	$18.37M	$17.75M
YoY Change	5.75%	3.49%	-3.45%
TOTAL ASSETS
Total Short-Term Assets	$43.66M	$61.85M	$26.01M
Total Long-Term Assets	$18.24M	$18.37M	$17.75M
Total Assets	$61.90M	$80.21M	$43.76M
YoY Change	-2.28%	83.32%	21.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.757M	$3.369M	$2.574M
YoY Change	-68.46%	30.91%	23.9%
Accrued Expenses	$13.70M	$16.14M	$11.31M
YoY Change	-3.81%	42.74%	103.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.89M	$19.89M	$15.23M
YoY Change	-32.12%	30.63%	25.2%
LONG-TERM LIABILITIES
Long-Term Debt	$33.18M	$32.83M	$0.00
YoY Change
Other Long-Term Liabilities	$2.358M	$4.298M	$1.878M
YoY Change	37.17%	10.82%	68.89%
Total Long-Term Liabilities	$2.358M	$37.13M	$1.878M
YoY Change	37.17%	857.38%	68.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.89M	$19.89M	$15.23M
Total Long-Term Liabilities	$2.358M	$37.13M	$1.878M
Total Liabilities	$55.56M	$57.13M	$19.19M
YoY Change	84.02%	197.66%	26.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$284.2M		-$177.8M
YoY Change	36.31%		55.56%
Common Stock	$113.0K		$75.00K
YoY Change	26.97%		68.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.342M	$23.08M	$24.56M
YoY Change
Total Liabilities & Shareholders Equity	$61.90M	$80.21M	$43.76M
YoY Change	-2.28%	83.32%	21.17%

Cashflow Statement

Concept	2022 Q1	2021	2020 Q4
OPERATING ACTIVITIES
Net Income	-$22.10M	-$84.40M	-$15.64M
YoY Change	-27.97%	32.91%	-1065.6%
Depreciation, Depletion And Amortization	$67.00K	$1.657M	$538.3K
YoY Change	-85.14%	-10.09%	-11.75%
Cash From Operating Activities	-$16.10M	-$70.90M	-$14.38M
YoY Change	-12.1%	74.89%	755.7%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$113.0K	$0.00
YoY Change	-100.0%	79.37%
Acquisitions
YoY Change
Other Investing Activities		$0.00	-$391.2K
YoY Change		-100.0%	117.32%
Cash From Investing Activities	$0.00	-$113.0K	-$391.2K
YoY Change	-100.0%	-101.02%	117.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$29.05M
YoY Change		-18.01%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$0.00	$106.8M	201.0K
YoY Change	-100.0%	138.39%	43.59%
NET CHANGE
Cash From Operating Activities	-$16.10M	-$70.90M	-14.38M
Cash From Investing Activities	$0.00	-$113.0K	-391.2K
Cash From Financing Activities	$0.00	$106.8M	201.0K
Net Change In Cash	-$16.07M	$35.76M	-14.57M
YoY Change	-182.45%	132.54%	746.85%
FREE CASH FLOW
Cash From Operating Activities	-$16.10M	-$70.90M	-$14.38M
Capital Expenditures	$0.00	$113.0K	$0.00
Free Cash Flow	-$16.10M	-$71.01M	-$14.38M
YoY Change	-12.2%	74.9%	755.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001534120
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20211231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.avalotherapeutics.com/20211231#PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesAndOtherLiabilities
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-37590
CY2020Q4	us-gaap	Inventory Net InventoryNet	3000	USD
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-0705648
CY2021	dei	Entity Registrant Name EntityRegistrantName	AVALO THERAPEUTICS, INC.
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	540 Gaither Road
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Rockville
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20850
CY2021	dei	City Area Code CityAreaCode	410
CY2021	dei	Local Phone Number LocalPhoneNumber	522-8707
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.001 Par Value
CY2021	dei	Trading Symbol TradingSymbol	AVTX
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	183500000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	112794203	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	Baltimore, Maryland
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54585000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18919000	USD
CY2021Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	1060000	USD
CY2020Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2177000	USD
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	3739000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2208000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	38000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	38000	USD
CY2020Q4	us-gaap	Assets Assets	43755000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61845000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	149000	USD
CY2021Q4	us-gaap	Assets Assets	80214000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2372000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2660000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	51000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	26005000	USD
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2695000	USD
CY2020Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1607000	USD
CY2021Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	1000000	USD
CY2020Q4	us-gaap	Disposal Group Including Discontinued Operation Other Noncurrent Assets DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets	0	USD
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	38000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1585000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	14409000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	14409000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	113000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	90000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3369000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2574000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11310000	USD
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0	USD
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	USD
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1341000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19888000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15225000	USD
CY2021Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	32833000	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2021Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	USD
CY2020Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	2000000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2298000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1878000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	57132000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	19193000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	112794203	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	112794203	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75004127	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75004127	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	113000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	75000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1257143	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1257143	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	285135000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	202276000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262166000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177790000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24562000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	80214000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6699000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1491000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	43755000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5398000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	300000	USD
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	59835000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32193000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	25549000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21832000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	17418000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2826000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2341000	USD
CY2021	avtx	Amortization Of Intangible Assets Continuing Operations AmortizationOfIntangibleAssetsContinuingOperations	1548000	USD
CY2020	avtx	Amortization Of Intangible Assets Continuing Operations AmortizationOfIntangibleAssetsContinuingOperations	1741000	USD
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	87532000	USD
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	79542000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-82134000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-72843000	USD
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	0	USD
CY2020	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	5208000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	409000	USD
CY2021	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-2391000	USD
CY2020	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	49000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2411000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5666000	USD
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-84545000	USD
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-67177000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-196000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2793000	USD
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-84349000	USD
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-64384000	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-27000	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	884000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-84376000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63500000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20996000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	0	USD
CY2020	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15496000	USD
CY2020	avtx	Issuance Of Shares Value Pursuant To Registered Direct Offering IssuanceOfSharesValuePursuantToRegisteredDirectOffering	5136000	USD
CY2020	avtx	Stock Issued During Period Value New Issues Private Placement StockIssuedDuringPeriodValueNewIssuesPrivatePlacement	3888000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	35428000	USD
CY2020	avtx	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	114000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	94000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	312000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6786000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63500000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	366000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24562000	USD
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	37653000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	861000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	1000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1567000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	8172000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-84376000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-84376000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23082000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-84376000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-63500000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	8172000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	6786000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1657000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1843000	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	794000	USD
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-22000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-197000	USD
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0	USD
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	25549000	USD
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	5208000	USD
CY2021	avtx	Disposal Group Including Discontinued Operation Change In Fair Value Of Guarantee DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee	0	USD
CY2020	avtx	Disposal Group Including Discontinued Operation Change In Fair Value Of Guarantee DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfGuarantee	1755000	USD
CY2021	avtx	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	0	USD
CY2020	avtx	Fair Value Adjustment Of Warrants And Investor Rights Obligation FairValueAdjustmentOfWarrantsAndInvestorRightsObligation	-14000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1117000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	678000	USD
CY2021	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	1531000	USD
CY2020	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2107000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1000000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	35000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-18000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-287000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1859000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	796000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	99000	USD
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0	USD
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	288000	USD
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	3250000	USD
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-196000	USD
CY2021	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-45000	USD
CY2020	avtx	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-2000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70892000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40539000	USD
CY2021	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	0	USD
CY2020	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	12837000	USD
CY2021	avtx	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	0	USD
CY2020	avtx	Payments For Asset Acquisitions PaymentsForAssetAcquisitions	1642000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	113000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-113000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	11132000	USD
CY2021	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	37653000	USD
CY2020	avtx	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0	USD
CY2021	avtx	Proceeds From Venture Debt Financing Agreement ProceedsFromVentureDebtFinancingAgreement	32900000	USD
CY2020	avtx	Proceeds From Venture Debt Financing Agreement ProceedsFromVentureDebtFinancingAgreement	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	29046000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	35428000	USD
CY2021	avtx	Proceeds From Issuance Of Common Stock Through Atm Program ProceedsFromIssuanceOfCommonStockThroughATMProgram	5230000	USD
CY2020	avtx	Proceeds From Issuance Of Common Stock Through Atm Program ProceedsFromIssuanceOfCommonStockThroughATMProgram	0	USD
CY2021	avtx	Proceeds From Registered Direct Offering ProceedsFromRegisteredDirectOffering	0	USD
CY2020	avtx	Proceeds From Registered Direct Offering ProceedsFromRegisteredDirectOffering	5136000	USD
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	3888000	USD
CY2021	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	1567000	USD
CY2020	avtx	Proceeds From Option Or Warrant Exercises ProceedsFromOptionOrWarrantExercises	114000	USD
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	366000	USD
CY2020	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	312000	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	94000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	106762000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44784000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	35757000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15377000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19106000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3729000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54863000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19106000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54863000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19106000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	1585000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	0	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	474000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1373000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	376000	USD
CY2021	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2020	us-gaap	Stock Issued1 StockIssued1	15496000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54585000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18919000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	51000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	38000	USD
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	227000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	149000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-262200000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-70900000	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Business<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo Therapeutics, Inc. (the “Company” or “Avalo”) is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology and rare genetic diseases. The Company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. Avalo’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2021, the Company changed its corporate name change from Cerecor Inc. to Avalo Therapeutics, Inc. and merged certain wholly-owned subsidiaries into the Company to consolidate its corporate structure. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avalo was incorporated and commenced operation in 2011 and completed its initial public offering in October 2015.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, Avalo had $54.6 million in cash and cash equivalents. In 2021, the Company closed three equity offerings for net proceeds of approximately $72.0 million (see Note 12 to the consolidated financial statements for more information). In June 2021, the Company entered into a $35 million venture debt financing agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (“Horizon”) and Powerscourt Investments XXV, LP (“Powerscourt”, together with Horizon, the “Lenders”). As of December 31, 2021, the Company had received the full $35 million. The Loan Agreement contains certain covenants and certain other specified events that could result in an event of default, which if not cured or waived, could result in the immediate acceleration of all or a substantial portion of the notes. As of the filing date of this Annual Report on Form 10-K, the Company was not aware of any breach of covenants, occurrence of material adverse change, nor had it received any notice of event of default from the Lenders (see Note 11 to the consolidated financial statements for more information). </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to meet its cash flow needs, the Company applies a disciplined decision-making methodology as it evaluates the optimal allocation of the Company’ resources between investing in the Company’s existing pipeline assets and acquisitions or in-licensing of new assets. For the year ended December 31, 2021, Avalo generated a net loss of $84.4 million and negative cash flows from operations of $70.9 million. As of December 31, 2021, Avalo had an accumulated deficit of $262.2 million. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern; however, losses are expected to continue as the Company continues to invest in its research and development pipeline assets. The Company will require additional financing to fund its operations and to continue to execute its business strategy at least one year after the date the financial statements included herein were issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To mitigate these conditions and to meet the Company’s capital requirements, management plans to use its current cash on hand along with some combination of the following: (i) dilutive and/or non-dilutive financings, (ii) federal and/or private grants, (iii) other out-licensing or strategic alliances/collaborations of its current pipeline assets, and (iv) out-licensing or sale of its non-core assets. If the Company raises additional funds through collaborations, strategic alliances or licensing arrangements with third parties, the Company might have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates. Subject to limited exceptions, our venture debt financing agreement prohibits us from incurring certain additional indebtedness, making certain asset dispositions, and entering into certain mergers, acquisitions or other business combination transactions without prior consent of the Lenders. If the Company requires but is unable to obtain additional funding, the Company may be forced to make reductions in spending, delay, suspend, reduce or eliminate some or all of its planned research and development programs, or liquidate assets where possible. Due to the uncertainty regarding future financing and other potential options to raise additional funds, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date that the financial statements in this Annual Report on Form 10-K were issued.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the long term, the Company’s ultimate ability to achieve and maintain profitability will depend on, among other things, the development, regulatory approval, and commercialization of its pipeline assets, and the potential receipt and sale of any priority review vouchers it receives.</span></div>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54600000	USD
CY2021	avtx	Sale Of Stock Number Of Equity Offerings SaleOfStockNumberOfEquityOfferings	3	offering
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	72000000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-84400000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including estimates related to but not limited to, revenue recognition, cost of product sales, stock-based compensation, fair value measurements, cash flows used in management's going concern assessment, income taxes, goodwill, and clinical trial accruals. The Company bases its estimates on historical experience and other market‑specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span></div>
CY2021	avtx	Accounts Receivable Payment Terms AccountsReceivablePaymentTerms	P60D
CY2021Q4	avtx	Accounts Receivable Prompt Payment Discount AccountsReceivablePromptPaymentDiscount	0.02
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company maintains a portion of its cash and cash equivalent balances in the form of a money market account with a financial institution that management believes to be creditworthy. The Company has no financial instruments with off‑balance sheet risk of loss.</span></div>
CY2021	avtx	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	2	contract
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2021Q3	avtx	Debt Instrument Remaining Contingent Consideration Liability DebtInstrumentRemainingContingentConsiderationLiability	3000000	USD
CY2021	avtx	Class Of Stock Number Of Classes Of Stock Outstanding ClassOfStockNumberOfClassesOfStockOutstanding	2	class_of_stock
CY2021	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	1676923	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2021Q4	avtx	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Exercised ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsExercised	308880	shares
CY2021Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2021Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2020Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	2981000	USD
CY2020Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	1784000	USD
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	286000	USD
CY2020Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	177000	USD
CY2021Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	2695000	USD
CY2020Q4	avtx	Property Plant And Equipment And Operating Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	1607000	USD
CY2021	us-gaap	Depreciation Depreciation	100000	USD
CY2021	avtx	Lessee Operating Lease Number Of Contracts LesseeOperatingLeaseNumberOfContracts	2	contract
CY2020	us-gaap	Depreciation Depreciation	100000	USD
CY2021	avtx	Lessee Operating Lease Remaining Lease Team LesseeOperatingLeaseRemainingLeaseTeam	P6Y6M
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2001000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	918000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2018000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1038000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1464000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.092
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	393000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	345000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	547000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	485000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	528000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	537000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	557000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	683000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3337000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	834000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2503000	USD
CY2020	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2021	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	2426000	USD
CY2020	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	900000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1741000	USD
CY2020Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	1585000	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1547000	USD
CY2021Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	38000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5956000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5918000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	38000	USD
CY2021	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y1M6D
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	6106000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4521000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1585000	USD
CY2020	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P0Y10M24D
CY2021Q4	avtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	8221000	USD
CY2020Q4	avtx	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	4939000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4310000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3120000	USD
CY2021Q4	avtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	1275000	USD
CY2020Q4	avtx	Accrued General And Administrative Expenses AccruedGeneralAndAdministrativeExpenses	771000	USD
CY2021Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	111000	USD
CY2020Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	31000	USD
CY2021Q4	avtx	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	1733000	USD
CY2020Q4	avtx	Accrued Sales Returns And Allowances AccruedSalesReturnsAndAllowances	1913000	USD
CY2021Q4	avtx	Accrued Medicaid Rebates AccruedMedicaidRebates	375000	USD
CY2020Q4	avtx	Accrued Medicaid Rebates AccruedMedicaidRebates	0	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	485000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	426000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	9000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	110000	USD
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	16519000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	11310000	USD
CY2021Q4	avtx	Number Of Class Of Stock Authorized NumberOfClassOfStockAuthorized	2	class_of_stock
CY2021Q4	avtx	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2021Q1	avtx	Class Of Warrant Or Right Percent Ownership Threshold ClassOfWarrantOrRightPercentOwnershipThreshold	0.0999
CY2021Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4400000	USD
CY2021	avtx	Share Based Compensation Arrangement By Share Based Payment Award Share Reserve Increase As Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardShareReserveIncreaseAsPercent	0.04
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8172000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6786000	USD
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	-439000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-219000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-2158000	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-218000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2597000	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	24000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-147000	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-2000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-49000	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	22000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-196000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-196000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2793000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31816000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	14935000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	4871000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2748000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3080000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2849000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	965000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	893000	USD
CY2021Q4	avtx	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	445000	USD
CY2020Q4	avtx	Deferred Tax Assets Installment Sale DeferredTaxAssetsInstallmentSale	462000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	381000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	543000	USD
CY2021Q4	avtx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	590000	USD
CY2020Q4	avtx	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	358000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	353000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	247000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	472000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	224000	USD
CY2021Q4	avtx	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	2020000	USD
CY2020Q4	avtx	Deferred Tax Assets Tax Difference In Tangible And Intangible Assets DeferredTaxAssetsTaxDifferenceInTangibleAndIntangibleAssets	1935000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	43343000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24252000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	43456000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24343000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	113000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	91000	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	avtx	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0148
CY2020	avtx	Effective Income Tax Rate Reconciliation Permanent Differences EffectiveIncomeTaxRateReconciliationPermanentDifferences	-0.0047
CY2021	avtx	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0
CY2019Q3	avtx	Royalty Agreement Period After Public Launch To Terminate Agreement RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement	P3Y
CY2020	avtx	Effective Income Tax Rate Reconciliation Built In Loss Percent EffectiveIncomeTaxRateReconciliationBuiltInLossPercent	0.0060
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0252
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0253
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	-0.0809
CY2021	avtx	Effective Income Tax Rate Reconciliation Nol Carryback To Cares Act Percent EffectiveIncomeTaxRateReconciliationNOLCarrybackToCARESActPercent	0.0026
CY2020	avtx	Effective Income Tax Rate Reconciliation Nol Carryback To Cares Act Percent EffectiveIncomeTaxRateReconciliationNOLCarrybackToCARESActPercent	0.0326
CY2021	avtx	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	-0.0015
CY2020	avtx	Effective Income Tax Rate Reconciliation Net Operating Loss Adjustment Per Section382 Percent EffectiveIncomeTaxRateReconciliationNetOperatingLossAdjustmentPerSection382Percent	-0.0016
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.2193
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.1446
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0022
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0421
CY2021Q1	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-2600000	USD
CY2021Q4	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	200000	USD
CY2019Q3	avtx	Royalty Agreement Payment Received RoyaltyAgreementPaymentReceived	2000000	USD
CY2019Q3	avtx	Royalty Agreement Buyout Option Percentage Of Net Present Value Of Royalty Payments RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments	0.75

Files In Submission

Name	View Source	Status
0001628280-22-004671-index-headers.html	Edgar Link	pending
0001628280-22-004671-index.html	Edgar Link	pending
0001628280-22-004671.txt	Edgar Link	pending
0001628280-22-004671-xbrl.zip	Edgar Link	pending
avtx-20211231.htm	Edgar Link	pending
avtx-20211231.xsd	Edgar Link	pending
avtx-20211231_cal.xml	Edgar Link	unprocessable
avtx-20211231_def.xml	Edgar Link	unprocessable
avtx-20211231_g1.jpg	Edgar Link	pending
avtx-20211231_htm.xml	Edgar Link	completed
avtx-20211231_lab.xml	Edgar Link	unprocessable
avtx-20211231_pre.xml	Edgar Link	unprocessable
ex-105_nonemployeedirector.htm	Edgar Link	pending
ex-211listofsubsidiariesof.htm	Edgar Link	pending
ex-2312021.htm	Edgar Link	pending
ex-3112021.htm	Edgar Link	pending
ex-3122021.htm	Edgar Link	pending
ex-3212021.htm	Edgar Link	pending
ex-415descriptionofregiste.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AVTX
Avalo Therapeutics, Inc. Stock $avtx

2022 Q1 Form 10-K Financial Statement

#000162828022004671 Filed on March 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX Avalo Therapeutics, Inc. Stock $avtx

2022 Q1 Form 10-K Financial Statement

#000162828022004671 Filed on March 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AVTX
Avalo Therapeutics, Inc. Stock $avtx